Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525127 | 0.86 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1MAPTHPGD | |
| SCHEMBL7526850 | 0.85 | PTPN1 (0.46) | PTPN1PTPN2MAPTGLO1 | |
| SCHEMBL7522308 | 0.85 | GLO1 (0.46) | PTPN1PTPN2ALDH1A1MAPTHPGD | |
| SCHEMBL7519972 | 0.83 | PTPN1 (0.44) | PTPN1PTPN2MAPTGLO1 | |
| SCHEMBL5837651 | 0.83 | DRD4 (0.46) | PTPN1PTPN2DRD4ALDH1A1MAPT | |
| SCHEMBL5838091 | 0.82 | PTPN1 (0.53) | PTPN1PTPN2DRD4GLO1 | |
| SCHEMBL7521500 | 0.82 | PTPN1 (0.43) | PTPN1PTPN2ALDH1A1GLO1 | |
| SCHEMBL7521290 | 0.81 | PTPN1 (0.54) | PTPN1PTPN2DRD4 | |
| SCHEMBL7524893 | 0.80 | PTPN1 (0.45) | PTPN1PTPN2ALDH1A1MAPTHPGD | |
| SCHEMBL7519093 | 0.80 | PTPN1 (0.46) | PTPN1PTPN2DRD4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | claimed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | claimed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | PTPN1 1/4885PTPN2 14/4885DRD4 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.